Simulations Plus Inc
NASDAQ:SLP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Simulations Plus Inc
Total Current Liabilities
Simulations Plus Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Simulations Plus Inc
NASDAQ:SLP
|
Total Current Liabilities
$10.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Total Current Liabilities
$1.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Total Current Liabilities
$96.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Total Current Liabilities
$156.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Total Current Liabilities
$476.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Total Current Liabilities
$218.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
What is Simulations Plus Inc's Total Current Liabilities?
Total Current Liabilities
10.3m
USD
Based on the financial report for Nov 30, 2025, Simulations Plus Inc's Total Current Liabilities amounts to 10.3m USD.
What is Simulations Plus Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
10%
Over the last year, the Total Current Liabilities growth was 6%. The average annual Total Current Liabilities growth rates for Simulations Plus Inc have been 9% over the past three years , 13% over the past five years , and 10% over the past ten years .
